Full Indication

U.S. Healthcare Professionals

Explore Treatment With OPDIVO and OPDIVO-based Combinations

Every patient or family member has a story to tell. Below are videos created to help you learn more about treatment with OPDIVO and OPDIVO-based combinations, including real patient experiences, how treatment works, and family members who share their experience and treatment journey.

John’s Story

Click to watch John's experience with OPDIVO® (nivolumab)

OPDIVO for People Who Have Had Prior Treatments for Non-Small Cell Lung Cancer

John is a husband, father of two, and a passionate golfer. Learn more about his experience with OPDIVO. (14:10)

For more information, see OPDIVO NSCLC clinical trial results.

Dave’s story

Click to watch Dave's experience with OPDIVO® (nivolumab)

OPDIVO® + YERVOY® (ipilimumab) for Newly Diagnosed Advanced Melanoma

Dave is a restaurant owner and father. Three different doctors agreed that OPDIVO + YERVOY was the right choice for him. (20:03)

For more information, see OPDIVO + YERVOY metastatic melanoma clinical trial results.

John’s story

OPDIVO for People Who Have Had Prior Treatments for Non-Small Cell Lung Cancer

John is a husband, father of two, and a passionate golfer. Learn more about his experience with OPDIVO. (14:10)

Both my wife and I cried. I can tell you one thing, that having cancer has made me take another look at golf.

OPDIVO will not work for everyone.
Individual results may vary.

Dave’s story

OPDIVO + YERVOY® (ipilimumab) for Newly Diagnosed Advanced Melanoma

Dave is a restaurant owner and father. Three different doctors agreed that OPDIVO + YERVOY was the right choice for him. (20:03)

Don’t ever lose hope.

OPDIVO and YERVOY will not work for everyone. Individual results may vary.

CAROL’S STORY

Click to watch Carol's experience with OPDIVO® (nivolumab)

OPDIVO + YERVOY for Certain Newly Diagnosed People With Advanced Kidney Cancer

After Carol was diagnosed, she spoke with her doctor about immunotherapy options. Together, they decided to start treatment with OPDIVO + YERVOY. (18:17)

For more information, see OPDIVO + YERVOY RCC clinical trial results.

Terry’s Story

Click to watch Terry's experience with OPDIVO® (nivolumab)

OPDIVO for People With Previously Treated Squamous Cell Carcinoma of the Head and Neck

Terry’s cancer kept returning with radiation and a platinum-based therapy. Learn more about his treatment with OPDIVO. (11:26)

For more information, see OPDIVO SCCHN clinical trial results.

Carol’s story

OPDIVO + YERVOY for Certain Newly Diagnosed People With Advanced Kidney Cancer

After Carol was diagnosed, she spoke with her doctor about immunotherapy options. Together, they decided to start treatment with OPDIVO + YERVOY. (18:17)

As a patient, you have to be your own advocate.

OPDIVO and YERVOY will not work for everyone. Individual results may vary.

Terry’s story

OPDIVO for People With Previously Treated Squamous Cell Carcinoma of the Head and Neck

Terry’s cancer kept returning with radiation and a platinum-based therapy. Learn more about his treatment with OPDIVO. (11:26)

It's tougher for the caregiver, I think

OPDIVO will not work for everyone. Individual results may vary.

John’S story

Click to learn more about John's advanced non-small cell lung cancer diagnosis story

OPDIVO + YERVOY for Certain Newly Diagnosed Adults with Advanced Non-Small Cell Lung Cancer That Tests Positive for PD-L1

John is a Navy veteran and a father of four who loves to travel. Find out more about John, a patient who received OPDIVO + YERVOY, and his experience being diagnosed with advanced lung cancer. (3:04)

For more information, see OPDIVO + YERVOY NSCLC clinical trial results.

JOHN & HIS NURSE JILLIAN

Watch an oncology nurse and her patient discuss starting treatment with OPDIVO® (nivolumab) + YERVOY® (ipilimumab).

An Oncology Nurse and Her Patient's Treatment Journey

Living with cancer can be challenging. Watch an oncology nurse and one of her patients share their experience with OPDIVO + YERVOY. While everyone’s cancer journey is different, they hope this video series may help others with their own cancer journey.

John’s story

OPDIVO + YERVOY for Certain Adults With Advanced Non-Small Cell Lung Cancer That Tests Positive for PD-L1

John is a Navy veteran and a father of four who loves to travel. Find out more about John, a patient who received OPDIVO + YERVOY, and his experience being diagnosed with advanced lung cancer. (3:04)

Utilize everything at your disposal, every option, look at every scenario in getting your treatment, then come up with the best treatment between you and your doctor.

OPDIVO will not work for everyone. Individual results may vary.

John & His Nurse Jillian
 

An Oncology Nurse and Her Patient’s Treatment Journey

Living with cancer can be challenging. Watch an oncology nurse and one of her patients share their experience with OPDIVO + YERVOY. While everyone’s cancer journey is different, they hope this video series may help others with their own cancer journey.

OPDIVO and YERVOY will not work for everyone. Individual results may vary.

All patients were compensated for their time in the creation of these videos.

MARCIA AND JOHN'S STORY

Click to see Marcia's Care & Share Experience

OPDIVO + YERVOY for Certain Newly Diagnosed Adults with Advanced Non-Small Cell Lung Cancer That Tests Positive for PD-L1

Marcia is the matriarch of her family of four. Find out more about her experience becoming a caregiver to her younger brother, John, after he was suddenly diagnosed with advanced lung cancer and began receiving OPDIVO. (3:23)

For more information, see OPDIVO + YERVOY NSCLC clinical trial results.

Claudia and John's Story

OPDIVO + YERVOY for Certain Newly Diagnosed People With Advanced Kidney Cancer

Hear how Claudia and John found strength together after learning about John's diagnosis. (3:23)

When you and your doctor decide on a treatment, it relieves a weight from your shoulders.

OPDIVO and YERVOY will not work for everyone. Individual results may vary.

Marcia and John’s story

OPDIVO + YERVOY for Certain Newly Diagnosed Adults with Advanced Non-Small Cell Lung Cancer That Tests Positive for PD-L1

Marcia is the matriarch of her family of four. Find out more about her experience becoming a caregiver to her younger brother, John, after he was suddenly diagnosed with advanced lung cancer and began receiving OPDIVO (3:23)

The most rewarding part about supporting John was finding and getting him on a treatment.

OPDIVO and YERVOY will not work for everyone. Individual results may vary.

All patients were compensated for their time in the creation of these videos.

TV COMMERCIAL

Click to learn more about OPDIVO® (nivolumab) plus YERVOY® (ipilimumab) treatment

OPDIVO + YERVOY for Advanced NSCLC

Discover a treatment option for certain adults with newly diagnosed advanced non-small cell lung cancer (NSCLC) that tests positive for PD-L1. (1:30)

OPDIVO + YERVOY VIDEO

Click to learn more about OPDIVO® (nivolumab) plus YERVOY® (ipilimumab) treatment

OPDIVO + YERVOY for Advanced Kidney Cancer

Discover a treatment option for certain people newly diagnosed with advanced kidney cancer. (2:23)

TV Commercial
OPDIVO + YERVOY is not approved for
patients younger than 18 years of age.

OPDIVO + YERVOY for Advanced NSCLC

Discover a treatment option for certain adults with newly diagnosed advanced non-small cell lung cancer (NSCLC) that tests positive for PD-L1. (1:30)

OPDIVO + YERVOY Video

OPDIVO + YERVOY for Advanced Kidney Cancer

Discover a treatment option for certain people newly diagnosed with advanced kidney cancer. (2:23)

OPDIVO + YERVOY VIDEO

Click to learn more about OPDIVO® (nivolumab) plus YERVOY® (ipilimumab) treatment

OPDIVO + YERVOY for Advanced Melanoma

Discover a treatment option for newly diagnosed adults with advanced melanoma. (2:25)

Patient Resources

Watch this video to learn more about the OPDIVO with You program

OPDIVO with You

Get complimentary support, tools, and educational resources with the OPDIVO with You Program. (3:30)

OPDIVO + YERVOY Video

OPDIVO + YERVOY for Advanced Melanoma

Discover a treatment option for newly diagnosed adults with advanced melanoma. (2:25)

OPDIVO with You

OPDIVO with You

Get complimentary support, tools, and educational resources with the OPDIVO with You Program. (3:30)

How OPDIVO + YERVOY WORKS

Click to watch how OPDIVO® and YERVOY® can work with your immune system

How OPDIVO + YERVOY Works

Discover how this combination immunotherapy treatment can work with your immune system. (2:08)

How OPDIVO Works

Click to watch how OPDIVO® can work with your immune system

How OPDIVO Works

Discover how this immunotherapy treatment can work with your immune system. (1:13)

How OPDIVO + YERVOY Works

How OPDIVO + YERVOY Works

Discover how this combination immunotherapy treatment can work with your immune system. (2:08)

How OPDIVO Works

How OPDIVO Works

Discover how this immunotherapy treatment can work with your immune system. (1:13)

SIGN UP FOR

OPDIVO® with You Program

Complimentary support, tools,
and educational resources
for
anyone considering or currently
taking OPDIVO.
Call 1-855-OPDIVO-1 or
click to learn more.

Sign Up Now
Watch this video to learn more about the OPDIVO with You program

Watch this video to learn more about the OPDIVO with You Program.

Getting an Infusion
Patient Resources

FULL INDICATIONS

For certain adults with advanced non-small cell lung cancer (NSCLC)

OPDIVO® (nivolumab) is a prescription medicine used in combination with YERVOY® (ipilimumab) as a first treatment for adults with a type of advanced stage lung cancer (called non-small cell lung cancer) when your lung cancer has spread to other parts of your body (metastatic) and your tumors are positive for PD-L1, but do not have an abnormal EGFR or ALK gene.

OPDIVO® (nivolumab) is a prescription medicine used in combination with YERVOY® (ipilimumab) and 2 cycles of chemotherapy that contains platinum and another chemotherapy medicine, as a first treatment for adults with a type of advanced stage lung cancer (called non-small cell lung cancer) when your lung cancer has spread or grown, or comes back, and your tumor does not have an abnormal EGFR or ALK gene.

OPDIVO (10 mg/mL) and YERVOY (5 mg/mL) are injections for intravenous (IV) use.

For people with previously treated advanced non-small cell lung cancer

OPDIVO® (nivolumab) is a prescription medicine used to treat people with a type of advanced stage lung cancer (called non-small cell lung cancer) that has spread or grown and you have tried chemotherapy that contains platinum, and it did not work or is no longer working. If your tumor has an abnormal EGFR or ALK gene, you should have also tried an FDA-approved therapy for tumors with these abnormal genes, and it did not work or is no longer working.

For people with advanced melanoma

OPDIVO® (nivolumab) is a prescription medicine used to treat people with a type of skin cancer called melanoma that has spread or cannot be removed by surgery (advanced melanoma).

OPDIVO® (nivolumab) is a prescription medicine used in combination with YERVOY® (ipilimumab) to treat people with a type of skin cancer called melanoma that has spread or cannot be removed by surgery (advanced melanoma).

OPDIVO (10 mg/mL) and YERVOY (5 mg/mL) are injections for intravenous (IV) use.

For people with melanoma after it and the affected lymph nodes have been removed by surgery to prevent it from coming back

OPDIVO® (nivolumab) is a prescription medicine used to treat people with a type of skin cancer called melanoma to help prevent melanoma from coming back after it and lymph nodes that contain cancer have been removed by surgery.

For certain people with advanced kidney cancer (renal cell carcinoma)

OPDIVO® (nivolumab) is a prescription medicine used in combination with YERVOY® (ipilimumab) to treat people with kidney cancer (renal cell carcinoma) in certain people when their cancer has spread.

OPDIVO (10 mg/mL) and YERVOY (5 mg/mL) are injections for intravenous (IV) use.

For newly diagnosed adults whose kidney cancer (renal cell carcinoma) has spread

OPDIVO® (nivolumab) is a prescription medicine used in combination with cabozantinib to treat people with kidney cancer when your cancer has spread (advanced renal cell carcinoma) and you have not already had treatment for your advanced RCC. Please read the Patient Information that comes with cabozantinib.

For people with previously treated advanced kidney cancer (renal cell carcinoma)

OPDIVO® (nivolumab) is a prescription medicine used to treat people with kidney cancer (renal cell carcinoma) when your cancer has spread or grown after treatment with other cancer medications.

For people with previously treated squamous cell carcinoma of the head and neck

OPDIVO® (nivolumab) is a prescription medicine used to treat people with head and neck cancer (squamous cell carcinoma) that has come back or spread and you have tried chemotherapy that contains platinum and it did not work or is no longer working.

For people with liver cancer (hepatocellular carcinoma) that have received treatment with sorafenib

OPDIVO® (nivolumab) is a prescription medicine used in combination with YERVOY® (ipilimumab) to treat people with liver cancer (hepatocellular carcinoma) if you have previously received treatment with sorafenib. OPDIVO in combination with YERVOY was approved based on response rate and how long patients’ responses lasted. There is ongoing evaluation of clinical benefit of OPDIVO in combination with YERVOY for this use.

OPDIVO (10 mg/mL) and YERVOY (5 mg/mL) are injections for intravenous (IV) use.

For people with previously treated advanced cancer in the bladder or urinary tract (urothelial carcinoma)

OPDIVO® (nivolumab) is a prescription medicine used to treat people with cancer of the lining of the urinary tract (including the bladder, urethra, ureters, or renal pelvis) [urothelial carcinoma] when it has spread or grown (locally advanced or metastatic) and you have tried chemotherapy that contains platinum, and it did not work or is no longer working or your cancer worsened within 12 months of treatment with chemotherapy that contains platinum, either before or after surgery to remove your cancer.

For people with a type of bladder or urinary tract cancer (urothelial carcinoma) to help prevent it from coming back after it was removed by surgery

OPDIVO® (nivolumab) is a prescription medicine used to treat people with cancer of the lining of the urinary tract (including the bladder, ureters, or renal pelvis) [urothelial carcinoma] to help prevent cancer of the urinary tract from coming back after it was removed by surgery.

For people 12 years of age and older whose CRC has spread to other parts of the body (metastatic), has progressed after treatment with a fluoropyrimidine, oxaliplatin, and irinotecan, and is MSI-H or dMMR

OPDIVO® (nivolumab) is a prescription medicine used in combination with YERVOY® (ipilimumab) to treat adults and children 12 years of age and older, with a type of colon or rectal cancer (colorectal cancer) that has spread to other parts of the body (metastatic), is microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR), and you have tried treatment with a fluoropyrimidine, oxaliplatin, and irinotecan, and it did not work or is no longer working. OPDIVO in combination with YERVOY was approved based on response rate and how long patients’ responses lasted. There is ongoing evaluation of clinical benefit of OPDIVO in combination with YERVOY for this use.

OPDIVO (10 mg/mL) and YERVOY (5 mg/mL) are injections for intravenous (IV) use.

OPDIVO® (nivolumab) is a prescription medicine used to treat adults and children 12 years of age and older with a type of colon or rectal cancer (colorectal cancer) that has spread to other parts of the body (metastatic), is microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR), and you have tried treatment with a fluoropyrimidine, oxaliplatin, and irinotecan, and it did not work or is no longer working. OPDIVO was approved based on response rate and how long patients’ responses lasted. There is ongoing evaluation of clinical benefit of OPDIVO for this use.

For adults with previously treated classical Hodgkin lymphoma including an autologous stem cell transplant whose cancer has come back or spread

OPDIVO® (nivolumab) is a prescription medicine used to treat adults with a type of blood cancer called classical Hodgkin lymphoma if your cancer has come back or spread after a type of stem cell transplant that uses your own stem cells (autologous), and you used the drug brentuximab vedotin before or after your stem cell transplant, or if you received at least 3 kinds of treatment including an autologous stem cell transplant. OPDIVO was approved based on response rate. There is ongoing evaluation of clinical benefit of OPDIVO for this use.

For people with previously treated advanced esophageal squamous cell cancer

OPDIVO® (nivolumab) is a prescription medicine used to treat people with cancer of the tube that connects your throat to your stomach (esophageal cancer) if your esophageal cancer is a type called squamous cell carcinoma, and cannot be removed with surgery, and has come back or spread to other parts of the body after you have received chemotherapy that contains fluoropyrimidine and platinum.

For adults newly diagnosed with malignant pleural mesothelioma (MPM)

OPDIVO® (nivolumab) is a prescription medicine used in combination with YERVOY® (ipilimumab) as a first treatment for adults with a type of cancer that affects the lining of the lungs and chest wall called malignant pleural mesothelioma which cannot be removed by surgery.

OPDIVO (10 mg/mL) and YERVOY (5 mg/mL) are injections for intravenous (IV) use.

For people with esophageal or gastroesophageal junction (GEJ) cancer who have been treated with chemoradiation followed by surgery to help prevent it from coming back

OPDIVO® (nivolumab) is a prescription medicine that may be used to help prevent cancer of the tube that connects your throat to your stomach (esophageal cancer) or cancer where the esophagus joins the stomach (gastroesophageal junction cancer) from coming back after it has been treated with chemoradiation followed by surgery to remove the cancer, but some cancer cells were still present in the removed tumor or lymph nodes.

For certain previously untreated adults with advanced gastric, gastroesophageal junction, and esophageal adenocarcinomas

OPDIVO® (nivolumab) is a prescription medicine used to treat people with cancer of the stomach (gastric), cancer where the esophagus joins the stomach (gastroesophageal junction), and in people with esophageal adenocarcinoma. OPDIVO may be used in combination with chemotherapy that contains fluoropyrimidine and platinum when your cancer cannot be removed with surgery or has spread to other parts of the body.

It is not known if OPDIVO is safe and effective in children younger than 12 years of age with MSI-H or dMMR metastatic colorectal cancer, or in children younger than 18 years of age for the treatment of any other cancers.

OPDIVO (10 mg/mL) and YERVOY (5 mg/mL) are injections for intravenous (IV) use.

Important Facts About OPDIVO® (nivolumab) and OPDIVO + YERVOY® (ipilimumab)

This is a summary of important information that you need to know about OPDIVO and OPDIVO + YERVOY. Your healthcare team can work with you to help answer any questions you may have about these medications. Keep this information in a safe place so you can refer to it before and during your treatment.

Look out for the following icons as you read:

  • Talk to your
    healthcare team
  • Call a healthcare
    provider right away
  • Helpful information
    to remember

What is the most important information I should know about OPDIVO + YERVOY?

OPDIVO and YERVOY are medicines that may treat certain cancers by working with your immune system. OPDIVO and YERVOY can cause your immune system to attack normal organs and tissues in any area of your body and can affect the way they work. Some of these problems may happen more often when OPDIVO is used in combination with another therapy.

Get medical help immediately if you develop any of these signs or symptoms or they get worse. It may keep these problems from becoming more serious. Your healthcare team will check you for these problems during treatment and may treat you with corticosteroid or hormone replacement medicines. If you have severe side effects, your healthcare team may also need to delay or completely stop your treatment.

What are the serious side effects of OPDIVO and OPDIVO + YERVOY?

A serious side effect is a side effect that can sometimes become severe or life-threatening and can lead to death. They may happen anytime during treatment or even after your treatment has ended. You may have more than one of these problems at the same time.

Call or see your healthcare provider right away if you develop any new or worse signs or symptoms, including:

Lung problems — Things to look out for may include:

  • new or worsening cough
  • shortness of breath
  • chest pain

Intestinal problems — Things to look out for may include:

  • diarrhea (loose stools) or more frequent bowel movements than usual
  • stools that are black, tarry, sticky, or have blood or mucus
  • severe stomach-area (abdominal) pain or tenderness

Liver problems — Things to look out for may include:

  • yellowing of your skin or the whites of your eyes
  • severe nausea or vomiting
  • pain on the right side of your stomach area (abdomen)
  • dark urine (tea colored)
  • bleeding or bruising more easily than normal

Hormone gland problems — Things to look out for may include:

  • headaches that will not go away or unusual headaches
  • eye sensitivity to light
  • eye problems
  • rapid heartbeat
  • increased sweating
  • extreme tiredness
  • weight gain or weight loss
  • feeling more hungry or thirsty than usual
  • urinating more often than usual
  • hair loss
  • feeling cold
  • constipation
  • your voice gets deeper
  • dizziness or fainting
  • changes in mood or behavior, such as decreased sex drive, irritability, or forgetfulness

Kidney problems — Things to look out for may include:

  • decrease in your amount of urine
  • blood in your urine
  • swelling of your ankles
  • loss of appetite

Skin problems — Things to look out for may include:

  • rash
  • itching
  • skin blistering or peeling
  • painful sores or ulcers in the mouth or nose, throat, or genital area

Eye problems — Things to look out for may include:

  • blurry vision, double vision, or other vision problems
  • eye pain or redness

Problems can also happen in other organs and tissues. These are not all the signs and symptoms of immune system problems that can happen with OPDIVO and YERVOY. Call or see your healthcare provider right away for any new or worsening signs or symptoms, which may include:

  • Chest pain, irregular heartbeat, shortness of breath, swelling of ankles
  • Confusion, sleepiness, memory problems, changes in mood or behavior, stiff neck, balance problems, tingling or numbness of the arms or legs
  • Double vision, blurry vision, sensitivity to light, eye pain, changes in eye sight
  • Persistent or severe muscle pain or weakness, muscle cramps
  • Low red blood cells, bruising

What are the possible side effects of OPDIVO + YERVOY?

OPDIVO and OPDIVO + YERVOY can cause serious side effects, including:

See the previous section, “What is the most important information I should know about OPDIVO + YERVOY?”

Severe infusion reactions — Things to look out for may include:

  • chills or shaking
  • itching or rash
  • flushing
  • shortness of breath or wheezing
  • dizziness
  • feel like passing out
  • fever
  • back or neck pain

Tell your healthcare team right away if you get these symptoms during an infusion of OPDIVO or YERVOY.

Complications, including graft-versus-host disease (GVHD), of bone marrow (stem cell) transplant that uses donor stem cells (allogeneic). These complications can be severe and can lead to death. These complications may happen if you underwent transplantation either before or after being treated with OPDIVO or YERVOY. Your healthcare provider will monitor you for these complications.

What are the most common side effects?

The most common side effects of OPDIVO when used alone include:

  • feeling tired
  • rash
  • pain in muscles, bones, and joints
  • itchy skin
  • diarrhea
  • nausea
  • weakness
  • cough
  • vomiting
  • shortness of breath
  • constipation
  • decreased appetite
  • back pain
  • upper respiratory tract infection
  • fever
  • headache
  • stomach-area (abdominal) pain
  • urinary tract infection

The most common side effects of OPDIVO when used in combination with YERVOY include:

  • feeling tired
  • diarrhea
  • rash
  • itching
  • nausea
  • pain in muscles, bones, and joints
  • fever
  • cough
  • decreased appetite
  • vomiting
  • stomach-area (abdominal) pain
  • shortness of breath
  • upper respiratory tract
    infection
  • headache
  • low thyroid hormone levels (hypothyroidism)
  • decreased weight
  • dizziness

The most common side effects of OPDIVO when used in combination with YERVOY and chemotherapy include:

  • feeling tired
  • pain in muscles, bones, and joints
  • nausea
  • diarrhea
  • rash
  • decreased appetite
  • constipation
  • itching

The most common side effects of OPDIVO when used in combination with cabozantinib include:

  • diarrhea
  • feeling tired or weak
  • liver problems
  • rash, redness, pain, swelling, or blisters on the palms of your hands or soles of your feet
  • mouth sores
  • rash
  • high blood pressure
  • low thyroid hormone levels
  • pain in muscles, bones, and joints
  • decreased appetite
  • nausea
  • change in the sense of taste
  • stomach-area (abdominal) pain
  • cough
  • upper respiratory tract infection

The most common side effects of OPDIVO when used in combination with fluoropyrimidine and platinum-containing chemotherapy include:

  • numbness, pain, tingling, or burning in your hands or feet
  • nausea
  • feeling tired
  • diarrhea
  • vomiting
  • decreased appetite
  • stomach-area (abdominal) pain
  • constipation
  • pain in muscles, bones, and joints

These are not all the possible side effects. Talk to your healthcare team or pharmacist for more information. You are encouraged to report side effects of prescription drugs to the FDA. Call 1-800-FDA-1088.

What should I discuss with my healthcare team before receiving OPDIVO or YERVOY?

Tell your healthcare provider about all your medical conditions, including if you:

  • have immune system problems such as Crohn’s disease, ulcerative colitis, or lupus
  • have received an organ transplant
  • have received or plan to receive a stem cell transplant that uses donor stem cells (allogeneic)
  • have received radiation treatment to your chest area in the past and have received other medicines that are like OPDIVO
  • have a condition that affects your nervous system, such as myasthenia gravis or Guillain-Barré syndrome
  • are pregnant or plan to become pregnant. OPDIVO and YERVOY can harm your unborn baby.
  • are breastfeeding or plan to breastfeed. It is not known if OPDIVO or YERVOY passes into your breast milk. Do not breastfeed during treatment with OPDIVO or YERVOY and for 5 months after the last dose of OPDIVO or YERVOY.

Females who are able to become pregnant:

Your healthcare provider should do a pregnancy test before you start receiving OPDIVO or YERVOY.

  • You should use an effective method of birth control during your treatment and for at least 5 months after the last dose of OPDIVO or YERVOY. Talk to your healthcare provider about birth control methods that you can use during this time.
  • Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment with OPDIVO or YERVOY. You or your healthcare provider should contact Bristol Myers Squibb at 1-844-593-7869 as soon as you become aware of a pregnancy.

Tell your healthcare provider about all the medicines you take, including:

  • prescription medicines
  • over-the-counter medicines
  • vitamins
  • herbal supplements

For more information, please see U.S. Full Prescribing Information and Medication Guide for OPDIVO,
and U.S. Full Prescribing Information and Medication Guide for YERVOY, or talk to your healthcare team.

Information provided on this website is not a substitute for talking with your healthcare professional.
Your healthcare professional is the best source of information about your disease.

All individuals depicted are models used for illustrative purposes only.

Bristol-Myers Squibb Corporate Site

Site Map | Legal Notice | Privacy Policy

© 2021 Bristol-Myers Squibb Company.

OPDIVO®, YERVOY®, Access Support®, and the related logos are registered trademarks of Bristol-Myers Squibb Company.

This site is intended for U.S. residents 18 years of age or older.

1506-US-2101473    11/21